Search
News
electroCore Q2 2026 Earnings: Revenue Rises 28% as Net Loss Narrows
electroCore (NASDAQ: ECOR) reported Q2 2026 net sales of $9.45 million, up approximately 28% year over year, while GAAP net loss narrowed 17% to $3.06 million and diluted loss per share improved to $0.33 from $0.44. Adjusted EBITDA loss improved 26% to $1.75 million. Growth came mainly from VA sales of Rx gammaCore and Quell, alongside higher Truvaga revenue, although gross margin slipped to 86.5% because of a larger inventory reserve. The company raised full-year 2026 revenue guidance to more than 30% growth.
TradingKey
Fri, Aug 7
SIGA Q2 2026 Earnings: Lower TPOXX Sales Compress Revenue and Margins
SIGA Technologies’ Q2 2026 revenue fell 49% year over year to $41.0 million, while diluted EPS declined to $0.17 from $0.49. Product sales totaled $37.9 million, including about $24 million of IV TPOXX delivered to the U.S. strategic national stockpile and $13 million of oral TPOXX sold to two international customers. Operating margin narrowed to 33.9% from 56.3%, reflecting lower sales and a different product mix as SIGA completed the final procurement order under the 19C contract.
TradingKey
Fri, Aug 7
Trevi Q2 2026 earnings: Clinical expansion raises R&D spending
Trevi Therapeutics’ Q2 2026 results reflected accelerating clinical investment rather than commercial revenue. R&D expense rose about 61% to $15.2 million as the company started the Phase 3 OCEAN-1 and Phase 2b LAKE trials, while the net loss widened to $17.8 million, or $0.11 per share. Cash, cash equivalents and marketable securities totaled $318.9 million after an April equity offering generated approximately $162.3 million in net proceeds. Trevi expects this capital to extend its runway into 2030, excluding Haduvio launch costs and a Phase 3 RCC trial.
TradingKey
Fri, Aug 7
Globus Medical Q2 2026 Earnings: Margin Expansion Lifts Adjusted EPS
Globus Medical’s (NYSE: GMED) Q2 2026 earnings showed net sales of $789.6 million, up 5.9% year over year, and GAAP diluted EPS of $1.10, down 26.2% because the prior-year quarter included a $110.5 million Nevro bargain purchase gain. Non-GAAP diluted EPS rose 55.8% to $1.34, while adjusted EBITDA margin expanded to 35.4%. Musculoskeletal Solutions and international sales led growth, offsetting a decline in Enabling Technologies. The company reaffirmed full-year revenue guidance and raised its non-GAAP EPS range to $4.95-$5.05 for 2026.
TradingKey
Fri, Aug 7
Relmada Q2 2026 earnings: R&D spending rises ahead of planned IND filings
Relmada Therapeutics’ Q2 2026 results showed a wider net loss of $12.9 million, or $0.11 per diluted share, as research and development expense nearly tripled to $8.4 million. Quarterly operating cash outflow increased to $9.6 million from $6.4 million, while cash, cash equivalents and short-term investments totaled $217.7 million at June 30. Management expects those resources to fund operations through 2029, including completion of NDV-01’s Phase 3 RESCUE program, as both lead programs move toward planned year-end 2026 IND filings.
TradingKey
Fri, Aug 7
Apyx Medical Q2 2026 Earnings: Surgical Aesthetics Drives 22% Revenue Growth
Apyx Medical reported Q2 2026 revenue of $13.9 million, up 22.1% year over year, as Surgical Aesthetics sales climbed 28.1% to $12.4 million. The GAAP net loss attributable to stockholders narrowed to $3.2 million, and the non-GAAP adjusted EBITDA loss improved to $0.7 million from $2.0 million. Gross margin rose to 63.9%, but operating cash use increased to $3.5 million on working-capital changes. The company reaffirmed FY2026 revenue guidance of $59.0 million to $60.0 million, led by continued Surgical Aesthetics growth.
TradingKey
Fri, Aug 7
CytomX Q2 2026 Earnings: Revenue Falls as R&D Spending Rises
CytomX Therapeutics’ Q2 2026 revenue fell to $1.4 million from $18.7 million, while diluted loss per share widened to $0.09 from a reported $0.00. Operating expenses rose to $25.2 million as Varseta-M manufacturing, personnel, consulting, and rent costs increased, contributing to a $20.7 million net loss. CytomX ended June with $330.3 million in cash, equivalents, and investments, excluding a $37.0 million Regeneron payment received in July. The company expects its cash runway to extend to at least the second half of 2028, with a Varseta-M update due by year-end.
TradingKey
Fri, Aug 7
Progyny Q2 2026 earnings: Margin expansion lifts profit faster than revenue
Progyny’s Q2 2026 revenue rose 5.3% to $350.5 million, while diluted EPS increased to $0.34 from $0.19 and gross margin expanded 180 basis points to 25.5%. Revenue grew 11.0% excluding a former large client’s $17.2 million prior-year contribution. Fertility services outpaced pharmacy growth, and adjusted EBITDA reached $62.1 million. The company guided to Q3 revenue of $335 million to $345 million and full-year revenue of $1.36 billion to $1.385 billion, with summer seasonality remaining a key issue.
TradingKey
Fri, Aug 7
Red Cat Q2 2026 earnings: Revenue rose 527% as losses widened
Red Cat’s Q2 2026 revenue rose 527% year over year to $20.2 million, and gross margin improved to 16.1% from about 11.6%. However, its GAAP net loss widened to $35.3 million, with diluted loss per share increasing to $0.26 from $0.15 as operating expenses climbed. The company ended June with $325.6 million in cash after substantial equity financing, while first-half operating cash use reached $78.7 million and inventory increased. Management reaffirmed its full-year revenue target of $150 million to $180 million.
TradingKey
Fri, Aug 7
Full House Resorts Q2 2026 earnings: New casinos lift adjusted EBITDA
Full House Resorts reported Q2 2026 revenue of $78.1 million, up 5.6% year over year, while diluted loss per share narrowed to $0.24 from $0.29. Adjusted EBITDA increased 19.5% to $13.3 million as American Place revenue rose 13.4% and Chamonix/Bronco Billy’s revenue grew 11.7%. Operating income improved to $2.3 million, but $10.8 million of net interest expense kept the company in a net loss. Liquidity at quarter-end was $48.4 million. Investors should monitor refinancing progress and construction financing for permanent American Place.
TradingKey
Fri, Aug 7
AOI Q2 2026 earnings: Record revenue brings non-GAAP profit as GAAP losses widen
Applied Optoelectronics (AOI) reported Q2 2026 revenue of $191.9 million, up 86.4% year over year, while GAAP diluted EPS was a $0.28 loss versus a $0.16 loss. Non-GAAP EPS improved to $0.06 as datacenter revenue more than doubled to $107.7 million and CATV revenue rose to $80.6 million. Gross margin narrowed, operating expenses increased, and the GAAP net loss widened to $22.8 million. AOI guided Q3 revenue to $255 million to $290 million while expanding 800G and 1.6 Tb production capacity, with demand expected to exceed capacity through mid-2027.
TradingKey
Fri, Aug 7
ICU Medical Q2 2026 Earnings: Organic Growth Supports Higher Guidance
ICU Medical’s Q2 2026 earnings showed revenue of $551.7 million, up 1% year over year, while organic revenue excluding the IV Solutions divestiture and currency increased 6%. Adjusted diluted EPS rose to $2.37 from $2.10, and free cash flow improved to $61.7 million from negative $8.5 million. Infusion Systems led product-line growth, although GAAP net income comparisons were affected by a prior-year divestiture gain and a current-quarter tariff refund. ICU Medical also raised its full-year 2026 GAAP and adjusted earnings guidance.
TradingKey
Fri, Aug 7
Arteris Q2 2026 Earnings: Record Revenue Comes With Wider GAAP Losses
Arteris reported Q2 2026 revenue of $24.1 million, up 46% year over year, while its GAAP net loss widened to $14.1 million, or $0.30 per share. ACV plus royalties rose 44% to $99.5 million and RPO increased 36% to $135 million, signaling continued contract and design activity. Quarterly free cash flow improved to $8.6 million, but the GAAP operating loss expanded to $13.9 million as operating expenses increased. The company also issued Q3 estimates and updated full-year 2026 guidance, including annual revenue of $95 million to $98 million.
TradingKey
Fri, Aug 7
Organogenesis Q2 2026 earnings: Revenue falls 58% as losses widen
Organogenesis reported Q2 2026 net product revenue of $42.8 million, down 58% year over year, while diluted GAAP loss per share widened to $0.77 from $0.10. Advanced Wound Care revenue fell 61%, and gross margin contracted to 45% from 73%, overwhelming lower SG&A spending. The company posted a $96.3 million net loss and cut its 2026 revenue outlook to $179 million–$215 million as the market recovery progressed more slowly than previously assumed. Cash, cash equivalents and restricted cash ended June at $46.8 million.
TradingKey
Fri, Aug 7
Westwood Q2 2026 Earnings: Revenue Growth Restores Operating Profit
Westwood Holdings Group’s (NYSE: WHG) Q2 2026 revenue rose approximately 9.6% year over year to $25.3 million, while diluted EPS increased to $0.17 from $0.12. GAAP operating income reached $2.1 million as revenue growth outpaced the increase in expenses, and non-GAAP Economic Earnings were $3.0 million. ETF assets surpassed $400 million and Private Capital assets exceeded $500 million, supporting higher asset-based advisory fees. Investors should monitor platform asset growth, compensation and professional-services costs, and how positive first-half operating cash flow affects the company’s cash balance.
TradingKey
Fri, Aug 7
Oculis Q2 2026 Results: Finance Gains Narrow the Net Loss
Oculis’ Q2 2026 results showed grant income of CHF0.31 million, a net loss of CHF9.97 million, and basic and diluted loss per share of CHF0.16. Operating loss widened to CHF23.57 million as administrative costs rose, while a CHF12.1 million warrant-liability gain and favorable currency movement narrowed the reported net loss. Cash, cash equivalents and short-term investments reached CHF228.3 million ($282.3 million), supporting runway into the second half of 2029 as Oculis advances Privosegtor and Licaminlimab.TradingKey
Fri, Aug 7
BCP Investment Q2 2026 Earnings: Portfolio Losses Push NAV Lower
BCP Investment (NASDAQ: BCIC) reported Q2 2026 total investment income of $15.2 million, up 20.1% year over year, while net investment income rose to $5.5 million but declined to $0.45 per share from $0.50. Net realized and unrealized investment depreciation of $15.0 million drove a $9.9 million decrease in net assets from operations and lowered NAV to $14.49 per share. Software-related valuation pressure was the main markdown concentration, while lower borrowings improved asset coverage and a post-quarter KeyBank amendment doubled committed capacity to $150 million.
TradingKey
Fri, Aug 7
Lifetime Brands Q2 2026 earnings: $40.1 million tariff refund drives profit swing
Lifetime Brands’ Q2 2026 revenue rose 7.4% year over year to $141.6 million, while diluted EPS improved to $0.87 from a $1.83 loss. A $40.1 million tariff refund lifted gross margin to 65.9% and drove much of the swing to profitability, including adjusted operating income. U.S. and International sales both grew, and six-month operating cash flow reached $46.0 million. The company maintained full-year sales guidance of $650 million to $700 million but raised its profit and EPS outlook to reflect the tariff refund.
TradingKey
Fri, Aug 7
Ziff Davis Q2 2026 Earnings: Goodwill Charge Drives Continuing-Operations Loss
Ziff Davis reported Q2 2026 revenue of $286.7 million, down 2.7% year over year, while diluted EPS from continuing operations fell to a $1.43 loss from $0.34 in earnings after a $54.8 million goodwill impairment. Adjusted diluted EPS rose 13.2% to $1.03 despite slightly lower adjusted net income, reflecting a smaller share count. Combined operating cash flow increased 55.9% to $89.0 million, and the Connectivity sale generated approximately $1.22 billion in total proceeds, sharply increasing quarter-end liquidity.
TradingKey
Thu, Aug 6
Nutex Health Q2 2026 Earnings: Arbitration Cost Relief Lifts Profit Despite Lower Revenue
Nutex Health (NASDAQ: NUTX) reported Q2 2026 revenue of $210.8 million, down 13.6%, while diluted EPS improved to $9.38 from a $2.95 loss. Quarterly operating cash flow rose to $34.2 million. Profitability benefited from lower arbitration-related contract services costs following a retroactive HaloMD amendment and a reduced CMS administrative fee, even as hospital revenue declined despite higher patient visits. The central question for investors is how much of the margin improvement will remain once the retroactive accounting benefit is no longer present.
TradingKey
Thu, Aug 6
Featured Tools
Top News
Meta Q3 Net Profit Surges 264% YoY, Raises Full-Year Capex Slightly; Shares Briefly Rise Over 4% After Hours
US Stocks Close: Nasdaq Drops 2.6%, SOX Falls Over 6%; Jensen Huang's Remarks on Capital Shortage Spark Financing Concerns, Meta Drops 7% After Earnings
Bloom Energy Q3 Revenue Up 138% YoY, EPS Swings to Profit, But Shares Tumble 7% After Hours
Memory Stocks Fall Over 4% as Micron Drops Below $900, Risking Another 16% Fall to Retest Lows
US Stocks Close: Nasdaq Gains Over 1%, Philadelphia Semiconductor Index Rises Nearly 2%; Tech Stocks Strengthen, SpaceX Gains Nearly 8% Post-Earnings
